Added to YB: 2026-06-15
Pitch date: 2026-06-10
RARE [neutral]
Ultragenyx Pharmaceutical Inc.
Author Info
No bio for this author
Company Info
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
Market Cap
$2.4B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.16
P/E
-3.99
EV/Sales
4.57
Sector
Biotechnology
Category
growth
GS Healthcare Conference – Recap (Day 2 – Part 2) - Ultragenyx Pharmaceutical Inc.
RARE (overview): Rare-disease platform at $22.79, M&A score 75. Pivotal H2 2026: Angelman Ph3 Aspire data (cognition endpoint) w/ durable 3-4yr Ph2 benefit, plus Sanfilippo Type A & GSD1A gene therapy approvals. Commercial prep underway, potential PRVs to bolster balance sheet. Multiple catalysts converging.
Read full article (1 min)